27 results
PRER14A
BXRXQ
Baudax Bio, Inc.
25 Aug 23
Preliminary revised proxy
4:01pm
Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding
DEFA14A
BXRXQ
Baudax Bio, Inc.
21 Aug 23
Additional proxy soliciting materials
8:05am
periods and the phase in periods specified in the applicable stock exchange rules (“Exchange Rules”), validly appointed an audit committee to oversee
8-K
EX-10.1
BXRXQ
Baudax Bio, Inc.
21 Aug 23
Entry into a Material Definitive Agreement
8:00am
committee to oversee internal accounting controls whose composition satisfies the applicable requirements of the Exchange Rules and the Company’s
DEFA14A
EX-99.1
BXRXQ
Baudax Bio, Inc.
9 Aug 23
Additional proxy soliciting materials
5:28pm
provide to physicians; and
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical
8-K/A
EX-99.1
3nhvbqk
9 Aug 23
Other Events
5:27pm
S-1/A
EX-10.35
nkvrgtunb
16 Aug 22
IPO registration (amended)
9:07pm
8-K
EX-10.1
xzx7rp guoqfya37znps
18 May 22
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-1.1
z2q8nrdt
1 Mar 22
Entry into a Material Definitive Agreement
7:01am
8-K
EX-10.1
yas86nu hh
28 Dec 21
Entry into a Material Definitive Agreement
4:42pm
8-K
EX-10.1
rvgc9v ld8kenc8
1 Jun 21
Entry into a Material Definitive Agreement
9:02am
8-K
EX-10.1
bgdou2 48u4xli
9 Feb 21
Entry into a Material Definitive Agreement
5:11pm
8-K
EX-10.1
u5hzqu7uo p79ftr8
18 Dec 20
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.1
84rmeil u2ilga
24 Nov 20
Entry into a Material Definitive Agreement
6:07am
8-K
EX-1.1
145wh4yja vsddv9o9
24 Mar 20
Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants
9:33am